Management and Pay

Management and Pay

The team facing Molina's 2025 profit break is led by the executive who pulled the company out of a deeper hole in 2017 — a $9.07-per-share loss that cost the founding family its jobs. That record is real, and the pay program has now gone almost entirely to zero as earnings fell, so the alignment is real too. Two uncertainties remain: whether a rate-and-policy squeeze is the kind of problem a turnaround operator can fix, and whether a retirement-eligible CEO stays for the attempt.

The same operator, a second downturn

Molina has been here before, and worse. In 2017 the company earned a pre-tax loss of $612 million on $19.9 billion of revenue, a medical care ratio of 90.6%, and a net loss of $9.07 per diluted share [1]. On May 2, 2017, the board terminated the company's chief executive and chief financial officer — both members of the founding Molina family — "specifically because of the Company's poor financial performance" [2].

The board hired Joseph Zubretsky as president and CEO in late 2017 [3], a career insurance operator with more than 35 years at firms including Aetna and The Hanover Group [4]. The recovery was fast: 2018 delivered $10.61 per diluted share on $707 million of net income and an 85.9% MCR [5], and by 2019 management could tell shareholders that "margin recovery is complete, margin sustainability is well under way, and the pivot to growth has begun" [6]. Zubretsky, still in the chair at age 69, is credited by the board with leading "the Company in its turnaround and growth plans" [7]. The five-year revenue tripling and record margins the rest of this report weighs were built on his watch.

Sources: 2019 Proxy Statement, 2017–2018 performance [8] [9]; FY2025 Annual Report, Financial Results Summary [10].

The comparison cuts two ways, and the difference in kind matters more than the difference in degree. The 2017 crisis was an outright loss, and the board treated it as a governance failure it could fix by changing the people — expansion into unprofitable markets and cost controls that a new operator could reverse. The 2025 break is milder on the page — a reduced profit of $8.92 per share, not a loss — but its cause sits outside management's direct control: an MCR that rose 260 basis points to 91.7% on higher medical utilization and acuity, on premium rates that states and CMS set (Margin Reset) [11]. A turnaround specialist can close unprofitable plans; he cannot legislate a rate increase. The precedent is genuine evidence this management can execute in a crisis, and an imperfect guide to whether it can fix this one.

Pay that went to zero

The clearest read on how management views its own performance is what its pay program did with it — and for 2023 through 2025, it paid almost nothing. For 2025, because adjusted earnings of $11.03 per diluted share fell below the plan threshold, the committee awarded no short-term cash bonus to any named executive; Zubretsky's $3.2 million target bonus paid $0 [12]. The three-year performance stock units granted in 2023, tied to cumulative 2023–2025 adjusted EPS, needed $59.36 to reach even threshold vesting; actual cumulative EPS came in at $54.56, so the entire tranche — 33,967 target units for the CEO — was forfeited without payment [13]. The 2024 and 2025 PSU grants, whose measurement periods run through 2026 and 2027, are now judged "not probable," and the company marked their fair value to zero at December 31, 2025 [14].

That flows straight through to realized pay. On the SEC's "compensation actually paid" measure — which marks equity to the share price each year — Zubretsky's pay fell from $75.9 million in 2021 to $15.4 million in 2024 and turned negative, minus $15.3 million, in 2025 [15]. The company notes the swing was driven largely by the stock, whose earlier gains reflected both results and an expanding forward multiple [16]. That is the mechanism working as intended: as the shares fell roughly two-thirds from their 2024 peak (Ownership and Options), the CEO's realized compensation went with them.

Source: FY2025 Proxy Statement, Pay Versus Performance; adjusted EPS over the same years ran $13.54, $17.92, $20.88, $22.65, then $11.03 [17].

The gap between granted and realized pay for 2025 is stark. Zubretsky's summary-table total was $18.3 million, of which $16.2 million was the grant-date value of stock awards; measured at the value those awards actually held on December 31, 2025 — with the PSUs at zero and only time-vested restricted shares retaining value — his total was $6.0 million [18]. The company underlined the point with its own supplemental pay ratio: 228-to-1 as granted, but 107-to-1 once the zeroed 2025 PSUs are excluded [19].

Source: FY2025 Proxy Statement, Summary Compensation Table (grant-date total $18.3M; value at 12/31/2025 $6.0M) and short-term bonus ($0 of a $3.2M target) [20] [21].

Two footnotes on this record are worth holding. First, a one-time special retention grant made to Zubretsky in the fall of 2024 was 100% performance-based, vesting only if adjusted EPS in fiscal 2027 reaches $32 at threshold and $36 at target; after the 2025 cost spike the committee now calls achievement "extremely unlikely," leaving the award at $0 value, and it has not modified the terms [22] [23]. That the grant is worthless is a sign of rigor, but the $32–$36 bar was set near the 2024 peak and sits well above management's own $25-by-2029 plan (Valuation and Buybacks) — so its lapse says more about how aggressive the original target was than about the base recovery path.

Second, the 2025 say-on-pay vote failed — a sharp break from the prior five years, which averaged over 90% support [24]. The board responded with an outreach program reaching holders of roughly 77% of shares; the principal concern was that same one-time special grant [25]. The episode is a modest governance demerit, but the response — engagement plus disclosure rather than a re-priced award — is consistent with the pay-for-performance stance the zeroed bonuses demonstrate.

Alignment, and where it stops

Zubretsky's incentives point the right way, but his cash conviction has limits. He beneficially owned 373,465 shares as of March 2026 — under 1% of the 52.1 million outstanding, but comfortably above the CEO's stock-ownership requirement of five times base salary [26] [27]. The entire officer-and-director group holds 749,230 shares, or 1.44% of the company [28]. That stake ties management to the outcome, and the forfeited awards mean insiders felt the drawdown. What is absent is fresh conviction: no insider has bought in the open market since 2018, including through the fall to the February 2026 low (Ownership and Options). Alignment here runs through retained and forfeited grants, not through executives adding shares at the bottom.

The board around him is conventional and independent — ten directors, nine of them independent, with an independent chairman and every committee composed exclusively of independent members; Zubretsky is the only insider on the board [29] [30]. This is the same board construct that fired the founders in 2017 and has since backed the current CEO through a full cycle.

What would change the read

The evidence supports a specific, bounded judgment. The management case is a genuine asset: the CEO in the chair engineered a complete recovery from a worse crisis, and a pay program that zeroed out three straight years of incentives is aligned rather than cosmetic. The strongest facts against leaning on it are three. The 2017 hole was a fixable operating failure; the 2025 squeeze runs on rates management does not set, so the prior turnaround is an imperfect template. The clearest alignment signal — near-zero realized pay — is also the company's own admission that even threshold three-year earnings targets are now out of reach. And the retention package built to hold the turnaround architect through 2027 is expected to pay nothing, against a CEO who can retire at will.

The read would strengthen if 2026–2027 results pull the cumulative PSU targets back toward threshold, or if insiders begin buying in the open market — either would convert "aligned by design" into "convinced by choice." It would weaken materially if Zubretsky signals departure, since the retention economics meant to keep him have lapsed and the bench has not been tested in his absence. For now, the people are a reason to take the recovery case seriously, not a reason to assume it.